Edoxaban Exposure in Patients With Atrial Fibrillation and Estimated Creatinine Clearance Exceeding 100 mL/min.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical pharmacology in drug development"
DOI: 10.1002/cpdd.1050
Abstract: Edoxaban 60 mg is approved for stroke prevention in patients with atrial fibrillation (AF) not fulfilling any dose-reduction criteria. As edoxaban is partially renally cleared (≈50%), this study compared pharmacokinetics (PK) and pharmacodynamics of edoxaban 60 mg… read more here.
Keywords: edoxaban exposure; atrial fibrillation; exposure; patients atrial ... See more keywords